Martin Worley Group Buys Shares of 10,168 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Martin Worley Group purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,168 shares of the specialty pharmaceutical company’s stock, valued at approximately $86,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp raised its stake in shares of KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after purchasing an additional 515,179 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $634,000. Barclays PLC grew its stake in shares of KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after acquiring an additional 54,257 shares in the last quarter. Readystate Asset Management LP bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $2,084,000. Finally, SG Americas Securities LLC boosted its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter.

Insider Activity

In other news, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the transaction, the chief executive officer now directly owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 236,055 shares of company stock valued at $2,162,146 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

KALV has been the topic of several analyst reports. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target for the company. Jones Trading reiterated a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, TD Cowen began coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.83.

KalVista Pharmaceuticals Trading Down 0.5 %

KALV stock opened at $11.09 on Thursday. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The business’s 50 day simple moving average is $10.73 and its 200 day simple moving average is $10.26. The firm has a market capitalization of $551.35 million, a PE ratio of -3.05 and a beta of 0.39.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).